2-(3-Cyclopropoxy-4-difluoromethoxyphenyl)-3-propyl-5-(2-trimethylsilylethoxymethyl)-1,5-dihydropyrrolo[2,3-d]pyridazin-4-one → 2-(3-Cyclopropoxy-4-difluoromethoxyphenyl)-3-(4-pyrazolyl)-1,5-dihydropyrrolo[2,3-d]pyridazin-4-one

HRID 2097395노트

반응식

HRID 2097395 반응식
[CH:1]1([O:4][C:5]2[CH:6]=[C:7]([C:15]3[NH:32][C:18]4[CH:19]=[N:20][N:21](COCC[Si](C)(C)C)[C:22](=[O:23])[C:17]=4[C:16]=3[C:33]3[CH:34]=[N:35][NH:36][CH:37]=3)[CH:8]=[CH:9][C:10]=2[O:11][CH:12]([F:14])[F:13])[CH2:3][CH2:2]1.C1(OC2C=C(C3NC4C=NN(COCC[Si](C)(C)C)C(=O)C=4C=3CCC)C=CC=2OC(F)F)CC1>>[CH:1]1([O:4][C:5]2[CH:6]=[C:7]([C:15]3[NH:32][C:18]4[CH:19]=[N:20][NH:21][C:22](=[O:23])[C:17]=4[C:16]=3[C:33]3[CH:34]=[N:35][NH:36][CH:37]=3)[CH:8]=[CH:9][C:10]=2[O:11][CH:12]([F:14])[F:13])[CH2:2][CH2:3]1

참가 물질

3

실험 절차

Reaction and post treatment were carried out in the same manner as in Example 6-(c) except for using 100 mg (0.189 mmol) of 2-(3-cyclopropoxy-4-difluoromethoxyphenyl)-3-(4-pyrazolyl)-5-(2-trimethylsilylethoxymethyl)-1,5-dihydropyrrolo[2,3-d]pyridazin-4-one obtained in Example 18-(b) in place of 2-(3-cyclopropoxy-4-difluoromethoxyphenyl)-3-propyl-5-(2-trimethylsilylethoxymethyl)-1,5-dihydropyrrolo[2,3-d]pyridazin-4-one, whereby 76 mg of the title compound was obtained as a pale yellowish solid substantially quantitatively.

후처리

  1. customReaction and post treatment

출처 및 근거

ORD 기록
ord-03acb4c789594f3cadc4005cf09705da
출처 데이터셋
uspto-grants-2013_05
특허 번호
US08450319B2

반응 노트

불러오는 중…